Position in KROS
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$230,736
-$239,580 QoQ
Shares Held
20,900
-9.5% QoQ
Ownership
0.105%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 76%
Shared 0%
None 24%
Common Shares in KROS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026LSV ASSET MANAGEMENT holds $1,914,392,782 across 14 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
2,275,145 | $548,241,690 | |
| 2 | INCY |
Incyte Corp
|
4,123,759 | $467,469,320 | |
| 3 | EXEL |
Exelixis, Inc.
|
8,146,478 | $443,249,867 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
253,200 | $157,880,328 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
1,410,257 | $110,380,815 | |
| 6 | HRMY |
Harmony Biosciences Holdings, Inc.
|
2,061,242 | $75,049,821 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
881,700 | $50,450,874 | |
| 8 | RIGL |
Rigel Pharmaceuticals Inc
|
721,666 | $28,231,573 |
All Filings in KROS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $230,736 | 20,900 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $470,316 | 23,100 | Shares | Sole | 2026-02-06 | |
| No filing history on record for this holder in this stock. | ||||||